Last reviewed · How we verify
Hydroxychloroquin
At a glance
| Generic name | Hydroxychloroquin |
|---|---|
| Also known as | Hydroxychloroquine Sulfate; Plaquenil, Plaquenil |
| Sponsor | Children's Hospital of Fudan University |
| Target | Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Discoid lupus erythematosus
- Falciparum malaria
- Malaria Prevention
- Ovale malaria
- Plasmodium Falciparum Malaria Prevention
- Plasmodium Malariae Malaria Prevention
- Plasmodium Ovale Malaria Prevention
- Quartan malaria
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Vivax malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
- Dizziness
- Fatigue
- Rash
- Pruritus
- Anorexia
Serious adverse events
- Cardiomyopathy
- Cardiac failure
- Ventricular tachycardia
- Torsades de pointes
- Retinopathy
- Aplastic anemia
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Fulminant hepatic failure
- Seizure
Key clinical trials
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (PHASE1)
- Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis (PHASE2)
- Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (NA)
- Hydroxychloroquin (HCQ) in chILD of Genetic Defect (NA)
- A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies (PHASE1)
- Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxychloroquin CI brief — competitive landscape report
- Hydroxychloroquin updates RSS · CI watch RSS
- Children's Hospital of Fudan University portfolio CI